^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD79b-targeted antibody-drug conjugate

    Related drugs:
    1m
    Efficacy and safety of Polatuzumab Vedotin in the real-world treatment of Chinese patients with aggressive B-cell non-Hodgkin lymphoma (ChiCTR2500107582)
    P4, N=600, Recruiting, Henan Cancer Hospital; Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital
    New P4 trial • HEOR • Real-world evidence
    |
    Polivy (polatuzumab vedotin-piiq)
    1m
    Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P1, N=165, Recruiting, AbbVie | Trial primary completion date: Nov 2031 --> Jan 2027
    Trial primary completion date • Adverse events • First-in-human
    1m
    Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD) (clinicaltrials.gov)
    P1/2, N=12, Recruiting, Washington University School of Medicine | Trial completion date: May 2031 --> May 2032 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Polivy (polatuzumab vedotin-piiq)
    1m
    Polatuzumab Vedotin Induced CD20 Upregulation Contributes to the Efficacy of Mosunetuzumab in Combination With Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Preclinical Models. (PubMed, EJHaem)
    These findings suggest that polatuzumab vedotin-induced CD20 upregulation provides a molecular rationale to explain the synergistic effect of this combination therapy. The authors have confirmed clinical trial registration is not needed for this submission.
    Preclinical • Journal
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CD79B (CD79b Molecule) • CD4 (CD4 Molecule)
    |
    Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
    2ms
    Diffuse large B-cell lymphoma in the new era: prognostic tools for mapping risk. (PubMed, Ann Hematol)
    R-CHOP remains the frontline standard, with polatuzumab-R-CHP conferring a subgroup-dependent progression-free survival gain, yet early relapse and primary refractoriness persist. On the other side, CNS risk assessment is best approached with CNS-IPI refined by site and genotype; prophylaxis remains individualized given mixed efficacy signals. Overall, risk-adapted, biologically driven care should report NCCN-IPI (alongside IPI) in all patients and incorporate imaging burden, genomics, and ctDNA where feasible.
    Review • Journal • IO biomarker
    |
    CD79B (CD79b Molecule) • PIM1 (Pim-1 Proto-Oncogene)
    |
    Rituxan (rituximab) • Polivy (polatuzumab vedotin-piiq)
    2ms
    First-line treatment with polatuzumab vedotin improves efficacy and survival in newly diagnosed patients with advanced diffuse large B-cell lymphoma: a multicentre retrospective analysis. (PubMed, Ann Med)
    Pola plus chemotherapy demonstrates superior efficacy and may prolong survival in patients with newly diagnosed advanced or high-risk DLBCL. However, it does not mitigate the unfavorable prognosis in patients with high P53 expression.
    Retrospective data • Journal
    |
    TP53 (Tumor protein P53) • CD79B (CD79b Molecule)
    |
    Polivy (polatuzumab vedotin-piiq)
    2ms
    Polatuzumab vedotin in CNS lymphoma: proof-of-concept study for blood-brain barrier penetration. (PubMed, Blood Adv)
    Interestingly, 2 of the 3 CNSL patients achieved a complete response to pola-based treatment. In summary, these data indicate pola is effective against pre-clinical CNSL models and can partially penetrate the BBB in CNSL patients, which together provide support for the evaluation of pola-based treatment in future clinical trials of primary and secondary CNSL.
    Journal
    |
    CD79B (CD79b Molecule)
    |
    Polivy (polatuzumab vedotin-piiq)
    2ms
    Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation (clinicaltrials.gov)
    P2, N=20, Recruiting, Weill Medical College of Cornell University | Trial completion date: Sep 2026 --> Sep 2027 | Trial primary completion date: Sep 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • prednisone • Polivy (polatuzumab vedotin-piiq)
    2ms
    Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) (clinicaltrials.gov)
    P3, N=306, Active, not recruiting, GWT-TUD GmbH | Trial primary completion date: Dec 2026 --> Dec 2025 | Trial completion date: Dec 2027 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD20 negative
    |
    carboplatin • Rituxan (rituximab) • ifosfamide • etoposide IV • Polivy (polatuzumab vedotin-piiq)
    2ms
    Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma (clinicaltrials.gov)
    P2, N=8, Active, not recruiting, Barbara Ann Karmanos Cancer Institute | Trial completion date: Jun 2025 --> Jul 2026
    Trial completion date
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Truxima (rituximab-abbs) • Polivy (polatuzumab vedotin-piiq) • methylprednisolone sodium succinate
    2ms
    G-Pola-GemOx in Refractory/Relapsed Aggressive B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, Navy General Hospital, Beijing
    New P2 trial
    |
    gemcitabine • oxaliplatin • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)